The online portal to be held on the Online page of the Medical Research Council of India (ICMR) will be a repository of all data similar to vaccine progression in India. You can access the online page from here.
“Everyone will have access to this online portal to see all recent data similar to studies, progression and clinical trials on these vaccines,” Vardhan said at the ICMR Centennial Chronology Press Convention.
Previous reports recommend that, initially, the ICMR vaccine portal will reflect data on the progression of the Covid-19 vaccine in India, however, over time, the Internet portal will be strengthened with the knowledge to be gained on all vaccines used to save their diseases. .
“The ICMR has tried to respond to the growing demands of clinical progress in biomedical studies, on the one hand, and the desire to find practical answers to the country’s fitness problems, on the other hand,” reads on the portal.
Vardhan at the press convention praised ICMR’s efforts and contributions in the field of science. “It is an honor for me to publish a 100-year chronology of CIMR’s history on its premises. The contributions of the scientists related to it are commemorated and serve as an inspiration to long-term scientists,” he added.
India is currently at other stages of clinical trials of 3 Covid-19 vaccines.
Phase III or the final level of the Covid-19 Covishield vaccine clinical trial, most recently in progression through the University of Oxford and manufactured through the Serum Institute of India (SII), began Monday at the state-run Sassoon General Hospital. Pune, Maharashtra, said a senior official.
The Covishield vaccine will be administered as a dose to 150 to 200 volunteers, official had said.
India’s indigenous vaccine developers Bharat Biotech International Ltd. are at the second-phase human trial stage and Zydus Cadila is in the process to receive approvals for conducting third-phase clinical trials.
Currently, the Uttar Pradesh government announced that phase-3 trial of the coronavirus vaccine ‘COVAXIN’ will start in Lucknow and Gorakhpur from October.
Moreover, India’s vaccine manufacturer recently announced a licensing agreement with Washington University School of Medicine in the US for a single dose intranasal vaccine for covid-19 based on a novel chimpanzee adenovirus. The pact gives the Hyderabad-based vaccine developer the rights to distribute the vaccine in all markets except the US, Japan and Europe, reported Mint.
Under the pact, phase I trials will take place in the university’s Vaccine and Treatment Evaluation Unit, while Bharat Biotech will undertake further stages of clinical trials in India and large-scale manufacturing of the vaccine at its facility in Genome Valley, Hyderabad.
SII has also started manufacturing Covid-19 vaccine candidate developed by Codagenix Inc, the US biotech said in a statement.
Dubbed as CDX-005, the coronavirus vaccine candidate has completed pre-clinical animal studies. The drug maker aims to initiate phase I clinical trial of its COVID-19 vaccine in the United Kingdom by the end of this year.
Meanwhile, Serum’s CEO Adar Poonawalla calling the distribution of a Covid-19 vaccine to 1.3 billion population of India, “concerning challenge” said that the government may need ₹80,000 crore over the next one year for distribution of covid-19 vaccine to every person in India.
Click here to read the Mint ePapermint is now on Telegram. Join mint channel in your Telegram and stay updated
Log in to our website to save your bookmarks. It’ll just take a moment.
Your session has expired, please login again.
You are now subscribed to our newsletters. In case you can’t find any email from our side, please check the spam folder.